ST PETER PORT, GUERNSEY / ACCESSWIRE / December 16, 2022 / Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) ("Goodbody" or the "Company"), today announces that that it has agreed to sell the Polish CBD related elements of its operations to Voyager Life PLC ("Voyager") in return for a consideration of £1.5m, comprising £0.5m cash and £1.0m convertible loan notes ("CLNs").
The divestment comprises the share sale of the Sativa Wellness Poland Sp. z.o.o. and Olimax NT Sp. z.o.o., that combined provide CBD extraction and manufacturing at the facility in Bilcza, Poland. Voyager will assume full operational control of the CBD extraction and manufacturing facility on 1 January 2023 with legal title passing following the conclusion of certain Polish registration requirements thereafter.
Under the CLNs, Voyager has three years to pay the Company plus annual interest at 7.5% paid quarterly. Goodbody has the right to convert the principal amount plus interest into up to approximately 2.5million Voyager Ordinary Shares. Until payment of the CLNs is made in full, Goodbody will retain security over the fixed assets of Sativa Wellness Poland Sp. z.o.o. and Olimax NT Sp. z.o.o.
Voyager is an AQSE quoted Growth Market company, offering a range of health and wellness products containing CBD and hemp seed oil. Products include oils, gummies (chewable sweets), bath products and skincare products, which are available online through the Company's website www.voyagercbd.com and also through third-party websites.
The Directors believe this to be a sound commercial decision allowing further funds to be directed towards the growing diagnostic and wellness sector of the Company which represents over 90% of revenues for 2021 and for 2022 YTD. It was determined that the levels of CBD sales undertaken by Goodbody Health were insufficient justification for meeting the costs of running a full extraction plant and the level of management input. This divestment also allows the management team to focus fully on the new opportunities available in the health and wellness business.
Goodbody will use the funds generated to continue to develop and expand its health and wellness operations. The Company continues to roll out its strategy of becoming a leading aggregator of innovative technology and innovative tests, including blood and genome, while identifying additional products to enable consumers to take more control of their life time health and wellbeing.
Voyager and Goodbody have established a strong working relationship. Voyager is now stocking Goodbody's blood diagnostic tests in its three stores and the two companies expect to continue to collaborate together on projects in the future. We will also continue to cooperate in the CBD market.
Geremy Thomas, Executive Chairman, said: "This transaction is great news for both Goodbody and Voyager, with each party moving closer towards their strategic goals. The cash Goodbody receives will be used to further both the expansion of the clinic network, investing into innovative testing technology, and into the range of available blood, genome and other diagnostic testing and minor treatment services. We look forward to exciting times ahead".
The directors of the Company accept responsibility for the contents of this announcement
The Financial Statements and Management Discussion and Analysis and further information regarding the Company can be found under the Company's profile on www.sedar.com.
On behalf of the Board of Directors,
Contact Information:
Geremy Thomas
Chief Executive Officer
+44 (0)20 7971 1255
enquiries@goodbodyhealth.com www.goodbodyhealth.com
Anne Tew
Chief Financial Officer
832-308-4975
enquiries@goodbodyhealth.comwww.goodbodyhealth.com
Cautionary Statement Regarding Forward-Looking Statements
Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release. This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Goodbody Health's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" "plan is" or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur", "will be achieved" or "shortly". The forward-looking information and forward-looking statements contained herein include but are not limited to: this being a sound commercial decision allowing further funds to be directed towards the growing diagnostic and wellness sector of the Company; the Company will use the funds generated to continue to develop and expand its health and wellness operations; the transaction is great news for both Goodbody and Voyager, with each party moving closer towards their strategic goals.
Although Goodbody Health believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statement including but not limited to: legal title passing following the conclusion of certain Polish registration requirements after 1 January 2023;
Goodbody Health does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
SOURCE: Goodbody Health Limited
View source version on accesswire.com:
https://www.accesswire.com/731846/Goodbody-Health-Announces-Cash-Injection-for-Growth-Through-Divestment-of-Polish-CBD-Operations
Related Quotes
Needham analyst Ryan Koontz maintained a Buy on Planet Labs (NYSE: PL) with a $9 price target. PL delivered a solid F3Q23 with revenue and Adjusted EBITDA well ahead of consensus, driven by robust demand in government and strength in commercial, albeit with some elevated scrutiny on spending with specific customers. Total revenue of $49.7 million increased 57% Y/Y and was 5% above consensus. Non-GAAP gross margin expanded 1,860bps Y/Y to 54%, well ahead of the high-end guidance, highlighting PL'
Well, the numbers came in this week, and the Fed did what we had all been expecting, while inflation beat the forecasts. That is, inflation slowed its rate of increase, from 7.7% in October to 7.1% in November, and the Federal Reserve responded by raising interest rates 50 basis points. And the next day, markets responded with a nosedive. The across-the-board drop came after investors had a chance to digest the numbers and the Fed’s recent comments. The Fed has signaled that while it will boost
Entrepreneurs sell out stock eventually, and Tesla CEO Elon Musk is no different. But he's still firmly in control of the company he co-founded.
Our 10 favorites from last year handily beat the market. Why we now like Alphabet, Bank of America, Medtronic, and seven others.
The Oracle of Omaha's $5.9 billion hidden portfolio is home to five amazing companies that are ripe for the picking.
A bad week for the market. Here's the bottom line.
In this article, we discuss the 14 best ARK stocks to buy now. If you want to skip the detailed analysis of ARK Investment Management and its hedge fund performance, skip directly to the 5 Best ARK Stocks To Buy Now. ARK Investment Management is one of the most renowned investment management firms in the […]
Space imaging company Maxar Technologies (NYSE: MAXR) has agreed to be acquired in a deal valued at $6.4 billion. The offer price is a massive premium over Maxar's Thursday close, and the shares are up 120% on Friday as a result. Maxar provides high-resolution imagery to a range of government and commercial customers, including the Department of Defense.
Shares of Novavax plunged to a two-year low on news that the company had to return $112.5 million to the UK government for unused vaccines.
The bulls probably don't want to hear this, but the bottom for this current bear market cycle may not be in place yet.
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.
Goldman Sachs Group Inc. plans to lay off up to 4,000 employees, or about 8% of its workforce, The New York-based investment bank also plans to cut, and in some cases eliminate, the annual bonuses of underperforming employees, according to The Wall Street Journal, citing unnamed sources familiar with the matter. Despite the job cuts, the bank will still have more employees than it did before the pandemic, the newspaper said. Goldman (NYSE: GS) employed more than 49,000 in September, compared with 38,000 at the end of 2019.
After soaring nearly 14% in early trading, Nikola shares were holding on to a gain of 7.5% as of 11:20 a.m. ET. Investors in hydrogen production company Plug Power (NASDAQ: PLUG) are moving that stock in the other direction after the announcement, however, with shares down 4% at that time. Nikola and Plug Power said yesterday they were initiating a strategic partnership intended to expand the use of hydrogen fuel.
Undoubtedly, 2022 was a year to forget for most technology stocks. Many excellent technology stocks are begging to be bought; Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), Adobe (NASDAQ: ADBE), and CrowdStrike Holdings (NASDAQ: CRWD) are three examples that could be among the market leaders in 2023. Jake Lerch (Alphabet): Buying $10,000 worth of Alphabet on March 13, 2020, took some guts.
The central bank raised interest rates by half a point and promised to hold rates higher for longer. That could be a problem.
(Bloomberg) — Elon Musk is seeking new investors for Twitter Inc. at $54.20 a share, the same price he paid when he took the company private for $44 billion in October and kicked off a contentious overhaul. Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesWorld’s Largest Hotel Aquarium Bursts Spilling 1,500 FishBinance, Alone at the Top After FTX, Stirs ‘Too Big to Fail’ Crypto WorryCovid Unleashed in Beijing Shows Rest of China What’s NextNobel Prize-W
Rivian (NASDAQ: RIVN) is one of the most talked about EV start-ups to hit the market in the past decade, but it hasn't done a lot to add value for investors. The hard truth is that it may be a while before Rivian is a profitable company. Using Tesla (NASDAQ: TSLA) as a proxy you can see below that Tesla wasn't generating positive free cash flow until 2019, nine years after it went public.
Oil stocks suffered a third straight day of falling share prices on Friday, with oil majors ExxonMobil (NYSE: XOM) and Chevron Corporation (NYSE: CVX) and pipeline operator Enterprise Products Partners (NYSE: EPD) all dropping sharply in early-morning trading. As of 10:50 a.m. EST, Exxon stock remains down 1.6%, Chevron has lost 1.8%, and Enterprise Products stock is down 2.4%. Tumbling oil prices were the cause.
(Bloomberg) — For all its twists and turns, the 2022 market has also been a story of patterns repeating. Stocks fall, shorts cover, quants buy, then everyone jumps back in just in time to get torched.Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesWorld’s Largest Hotel Aquarium Bursts Spilling 1,500 FishBinance, Alone at the Top After FTX, Stirs ‘Too Big to Fail’ Crypto WorryCovid Unleashed in Beijing Shows Rest of China What’s NextNobel Prize-Winning
“Investor frustration is building as the Musk brand has quickly deteriorated over the past six months,” the influential tech analyst wrote. “The Twitter nightmare continues.”
